Gene modification may benefit human neurological disorders such as Alzheimer's disease (AD). Grafting cells to the brain that are genetically modified to secrete a specific molecule potentially permits chronic, well- tolerated and regionally specific substance delivery. In AD, this approach could be utilized to administer trophic agents such as nerve growth factor (NGF) to the brain to retard cholinergic neuronal degeneration, or to replenish neurotransmitter deficiencies including losses of acetylcholine, serotonin, norepinephrine, or peptides. This approach might also be utilized to replenish or block substances that potentially contribute to AD development, such as neurofilament or beta-amyloid protein abnormalities. This project will examine whether gene therapy can prevent cholinergic neuronal degeneration in the adult primate brain and restore morphological and/or behavioral deficits that occur in aged primates. Although deficiencies of multiple transmitter systems occur in AD, cholinergic neuronal degeneration is targeted in this proposal for several reasons: 1) Disturbances of cholinergic function in both animals and in human volunteers result in memory loss, a cardinal feature of AD. 2) Both the clinical severity of AD and the severity of a pathological marker of the disease, senile plaques, correlate with losses of cholinergic neuronal markers. 3) Degeneration of cholinergic neurons in the adult brain can be prevented by NGF infusions, providing a useful model for degenerative disorders. The goals of this project are to transduce primary primate fibroblasts with the cDNAs for NGF or ChAT (the biosynthetic enzyme for acetylcholine), then characterize the survival and expression of these transgenes in vitro and in vivo. The synthesis, secretion and biological activity of transgene products will be assessed. Finally, the extent to which transgeneic cells can induce neuronal repair and/or functional recovery in model systems of cholinergic loss, aging, and AD will be assessed.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG010435-04
Application #
3746192
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Nagahara, Alan H; Wilson, Bayard R; Ivasyk, Iryna et al. (2018) MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates. Gene Ther 25:104-114
Chen, Zhijiang; Donnelly, Christopher R; Dominguez, Bertha et al. (2017) p75 Is Required for the Establishment of Postnatal Sensory Neuron Diversity by Potentiating Ret Signaling. Cell Rep 21:707-720
Hirai, Maretoshi; Arita, Yoh; McGlade, C Jane et al. (2017) Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. J Clin Invest 127:569-582
Overk, Cassia; Masliah, Eliezer (2017) Perspective on the calcium dyshomeostasis hypothesis in the pathogenesis of selective neuronal degeneration in animal models of Alzheimer's disease. Alzheimers Dement 13:183-185
Kratter, Ian H; Zahed, Hengameh; Lau, Alice et al. (2016) Serine 421 regulates mutant huntingtin toxicity and clearance in mice. J Clin Invest 126:3585-97
van den Hurk, Mark; Kenis, Gunter; Bardy, Cedric et al. (2016) Transcriptional and epigenetic mechanisms of cellular reprogramming to induced pluripotency. Epigenomics 8:1131-49
Biane, Jeremy S; Takashima, Yoshio; Scanziani, Massimo et al. (2016) Thalamocortical Projections onto Behaviorally Relevant Neurons Exhibit Plasticity during Adult Motor Learning. Neuron 89:1173-1179
Spencer, Brian; Desplats, Paula A; Overk, Cassia R et al. (2016) Reducing Endogenous ?-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. J Neurosci 36:7971-84
Xu, Jiqing; de Winter, Fred; Farrokhi, Catherine et al. (2016) Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model. Sci Rep 6:31692
Spencer, Brian; Potkar, Rewati; Metcalf, Jeff et al. (2016) Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease. J Biol Chem 291:1905-20

Showing the most recent 10 out of 183 publications